fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Advertisment

FDA approves EndeavorRx, a prescription treatment for children with ADHD.- Akili

Written by | 19 Jun 2020 | Pharmacy

Akili has announced that the FDA has granted clearance for EndeavorRx (AKL-T01) as a prescription treatment for children with attention-deficit/hyperactivity disorder (ADHD).

Delivered through a captivating video game experience, EndeavorRx is indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Persistent attention issues have a significant impact on the daily lives of millions of people. Attention impairments are a key component of ADHD for many children yet are often overshadowed by more overt symptoms of ADHD.

EndeavorRx was reviewed through FDA’s de novo pathway and its clearance creates a new class of digital therapeutics. EndeavorRx is designed to directly target and activate neural systems through the presentation of sensory stimuli and motor challenges to improve cognitive functioning..

Using EndeavorRx, patients navigate a character through different worlds while avoiding obstacles and collecting targets to unlock new worlds and receive awards. The captivating experience of ENDEAVOR is designed to drive engagement and compliance.

Comment: This FDA decision is a notable milestone in the FDA’s regulation of digital therapeutics, products that use software to help prevent, manage or treat a range of health conditions. Akili’s product is the first game-based therapeutic FDA has approved for any indication and the first digital therapeutic targeting symptoms associated with ADHD.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.